Biotech Drug Report Generated Jul 13, 2026

ENBUMYST

ESPR·Esperion Therapeutics, Inc.

NEUTRAL

Drug Impact Rating0/10

Trial Phase: Approved
Time to Market: Already FDA-approved and launched (FDA approval September 14, 2025)
Why 0/10: ENBUMYST is already FDA-approved (September 14, 2025) and in early commercialization. ESPR was acquired by ArchiMed and taken private on July 13, 2026, there is no public equity tied to this drug anymore. No upcoming binary catalyst for a public stock.

Actionable Insight NEUTRAL

ESPR has been delisted following ArchiMed's acquisition at $3.16/share. Former shareholders received one non-transferable CVR per share, tied to U.S. sales milestones for ENBUMYST and bempedoic acid products through 2030. There is no public equity vehicle to trade for exposure to this drug's commercial performance.

Price Chart

Loading chart...

Executive Summary

ENBUMYST (bumetanide nasal spray) is the first and only FDA-approved intranasal loop diuretic, approved September 14, 2025 for short-term treatment of edema associated with congestive heart failure, hepatic disease, and renal disease. It was developed by private Corstasis Therapeutics, which was acquired by Esperion (ESPR) for $75M upfront plus milestones in March 2026. However, ESPR itself was then acquired by private equity firm ArchiMed for $3.16/share (~$1.1B) and taken private, closing July 13, 2026. There is no publicly traded equity for this drug going forward. Former ESPR shareholders received CVRs tied to sales milestones but these are non-transferable.

How It Works

ENBUMYST is a nasal spray version of bumetanide, a loop diuretic (a "water pill") that helps the kidneys remove excess fluid from the body. It is used short-term to treat edema (fluid retention) in adults with congestive heart failure, liver disease, or kidney disease. The nasal spray absorbs 33% faster than oral bumetanide and provides a predictable response similar to IV therapy, but in a convenient at-home format.

Trial Status

FDA-approved on September 14, 2025. Commercially launched by Corstasis, then Esperion post-acquisition (closed April 2, 2026). Now owned by ArchiMed via the Esperion take-private that closed July 13, 2026.

The Two-Sided Case

▲ Bull Case4

ENBUMYST is the first FDA-approved intranasal loop diuretic, a novel delivery format for a well-established drug, with 33% faster absorption than oral bumetanide.

The addressable U.S. market for outpatient diuretic therapy in edema is estimated at a multi-billion-dollar opportunity, targeting ~6.7 million American adults with heart failure (sources: Corstasis BusinessWire press release, Intellectia.AI).

Patents extend to at least December 2040–May 2045, providing long exclusivity runway for the nasal spray formulation (source: Drugs.com, GreyB patent analysis).

Esperion had deployed 155 sales reps for the full commercial launch, leveraging its existing cardiovascular sales infrastructure for bempedoic acid (source: Intellectia.AI Needham conference update).

▼ Bear Case4

ESPR is delisted and taken private, there is no publicly traded stock to invest in for this drug. Former shareholders received $3.16/share cash plus non-transferable CVRs with uncertain payout.

Bumetanide itself is a generic drug first FDA-approved in 1983, the innovation is purely the delivery format, not a new molecular entity, which may limit pricing power and reimbursement. Oral and IV bumetanide generics are widely available.

The Corstasis acquisition cost $75M upfront plus up to $180M in milestones and ongoing royalties, a meaningful cash outlay for a product entering a competitive diuretic market with established cheap alternatives (source: Fierce Pharma / Investing.com).

Analyst consensus on ESPR before delisting was weak: 0 buys, 8 holds, 1 sell, 2 strong sells with a mean price target of $3.19 vs the $3.16 acquisition price.

Upcoming Catalysts

No public equity catalysts, ESPR is delisted. CVR milestone payments (up to $100M aggregate) are contingent on U.S. net sales of ENBUMYST and bempedoic acid products; any milestone announcements would affect CVR value but these are non-transferable to new investors.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Esperion Therapeutics, Inc. 8-K ESPR ·Originating report

Sources · 10

Hover a chip for the title

1 fiercepharma.com2 businesswire.com3 accessdata.fda.gov4 managedhealthcareexecutive.com5 drugs.com6 drugs.com7 sec.gov8 businesswire.com9 intellectia.ai10 fiercepharma.com